Abstract | BACKGROUND: METHODS: Sixty-eight consecutive adults with de novo ALL or lymphoblastic lymphoma were treated with this modified hyper-CVAD regimen inclusive of rituximab for CD20 expression≥20%. RESULTS: Sixty-three (93%) patients achieved complete response (CR). With a median follow-up of 90 months, the 5-year CR duration (CRD) and overall survival (OS) rates were 46% and 44%, respectively. Compared with 208 patients treated with standard hyper-CVAD (rates of 45% and 47%, respectively; P=not significant), outcome with the modified hyper-CVAD regimen was not improved overall. Outcome was improved by the addition of rituximab for the CD20-positive subset (rates of CRD and OS of 50% and 53%, respectively), whereas anthracycline intensification worsened outcome for the CD20-negative subset (rates of CRD and OS of 41% and 35%, respectively; P=.01) compared with standard hyper-CVAD. A high mortality rate related to infections in CR was noted among patients aged 60 years or older. CONCLUSIONS:
|
Authors | Deborah Thomas, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Elias Jabbour, Sherry Pierce, Jorge Cortes, Hagop Kantarjian |
Journal | Cancer
(Cancer)
Vol. 116
Issue 19
Pg. 4580-9
(Oct 01 2010)
ISSN: 0008-543X [Print] United States |
PMID | 20572037
(Publication Type: Journal Article)
|
Copyright | Copyright © 2010 American Cancer Society. |
Chemical References |
- Anthracyclines
- Cytarabine
- Vincristine
- Dexamethasone
- Doxorubicin
- Cyclophosphamide
- Methotrexate
- Daunorubicin
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anthracyclines
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Cyclophosphamide
(administration & dosage)
- Cytarabine
(administration & dosage)
- Daunorubicin
(administration & dosage)
- Dexamethasone
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Drug Administration Schedule
- Humans
- Methotrexate
(administration & dosage)
- Middle Aged
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, mortality)
- Salvage Therapy
- Treatment Outcome
- Vincristine
(administration & dosage)
|